Upper gastrointestinal cancers global burden profile, trends, contributors, and attributable change in life expectancy from 1990 to 2021.
1/5 보강
[BACKGROUND] Upper gastrointestinal (GI) cancers, comprising esophageal cancer (EC) and gastric cancer (GC), remain a significant global health burden with disproportionate geographic distribution of
APA
Teng Y, Zhang H, et al. (2026). Upper gastrointestinal cancers global burden profile, trends, contributors, and attributable change in life expectancy from 1990 to 2021.. Journal of the National Cancer Center, 6(2), 166-174. https://doi.org/10.1016/j.jncc.2026.02.005
MLA
Teng Y, et al.. "Upper gastrointestinal cancers global burden profile, trends, contributors, and attributable change in life expectancy from 1990 to 2021.." Journal of the National Cancer Center, vol. 6, no. 2, 2026, pp. 166-174.
PMID
42007221
Abstract
[BACKGROUND] Upper gastrointestinal (GI) cancers, comprising esophageal cancer (EC) and gastric cancer (GC), remain a significant global health burden with disproportionate geographic distribution of incidence and mortality. A comprehensive assessment of global and regional patterns and trends of upper GI cancer burden is essential to inform targeted prevention strategies.
[METHODS] Data were sourced from the Global Burden of Disease (GBD) study 2021. We examined the incidence, mortality, and life expectancy (LE) impacts of upper GI cancers from 1990 to 2021 across 21 GBD world regions. Trends were assessed using age-standardized rates and average annual percentage change (AAPC). Non-modifiable demographic factors and modifiable risk-attributable burdens were analyzed. A three-step decomposition method was applied to quantify the contribution of upper GI cancer to changes in LE.
[RESULTS] In 2021, upper GI cancers accounted for 1.80 million new cases and 1.49 million deaths globally, with Asia contributing over 70% of the burden. Global age-standardized incidence and mortality rates for upper GI cancers declined from 1990 to 2021, with AAPC of -1.53% and -1.87%, respectively, although absolute incidence and deaths increased due to population growth and ageing, contributing to 1.13 million deaths for upper GI cancers. Population expansion and ageing drove increases in age-related deaths during the study period and were offset by reduced incidence and case fatality. Risk-attributable deaths declined for most modifiable factors, with tobacco remaining the leading risk, responsible for 21.9% of all deaths. A total of 0.24 year of LE gained was attributable to upper GI cancers from 1990 to 2021. Regionally, high-income Asia Pacific achieved the greatest gains in LE (0.67 years). GC predominantly contributed to the most gains, whereas EC mostly contributed to LE changes in Central and East Asia (0.27 years and 0.19 years, respectively).
[CONCLUSIONS] Although the burden of upper GI cancers has declined, progress is uneven, and the absolute burden remains high in Asia. Continued region-specific prevention, risk factor control, and equitable access to early detection and treatment are essential to further reduce the disease burden and close global disparities.
[METHODS] Data were sourced from the Global Burden of Disease (GBD) study 2021. We examined the incidence, mortality, and life expectancy (LE) impacts of upper GI cancers from 1990 to 2021 across 21 GBD world regions. Trends were assessed using age-standardized rates and average annual percentage change (AAPC). Non-modifiable demographic factors and modifiable risk-attributable burdens were analyzed. A three-step decomposition method was applied to quantify the contribution of upper GI cancer to changes in LE.
[RESULTS] In 2021, upper GI cancers accounted for 1.80 million new cases and 1.49 million deaths globally, with Asia contributing over 70% of the burden. Global age-standardized incidence and mortality rates for upper GI cancers declined from 1990 to 2021, with AAPC of -1.53% and -1.87%, respectively, although absolute incidence and deaths increased due to population growth and ageing, contributing to 1.13 million deaths for upper GI cancers. Population expansion and ageing drove increases in age-related deaths during the study period and were offset by reduced incidence and case fatality. Risk-attributable deaths declined for most modifiable factors, with tobacco remaining the leading risk, responsible for 21.9% of all deaths. A total of 0.24 year of LE gained was attributable to upper GI cancers from 1990 to 2021. Regionally, high-income Asia Pacific achieved the greatest gains in LE (0.67 years). GC predominantly contributed to the most gains, whereas EC mostly contributed to LE changes in Central and East Asia (0.27 years and 0.19 years, respectively).
[CONCLUSIONS] Although the burden of upper GI cancers has declined, progress is uneven, and the absolute burden remains high in Asia. Continued region-specific prevention, risk factor control, and equitable access to early detection and treatment are essential to further reduce the disease burden and close global disparities.
같은 제1저자의 인용 많은 논문 (5)
- Proliferative Tumor States and Immunogenic Ecosystems Predict Neoadjuvant Chemotherapy Response in Triple-Negative Breast Cancer.
- Single-port Non-liposuction Endoscopic Axillary Lymph Node Dissection in Breast Cancer Surgery.
- The mediating role of resourcefulness in the relationship between perceived stress and benefit finding among non-small cell lung cancer patients: a cross-sectional study.
- Raddeanin A promotes the apoptosis of gastric cancer in conjunction with autophagy inhibitor Hydroxychloroquine via MAPK signaling pathway.
- Disruption of the biorhythm in gastric epithelial cell triggers inflammation in Helicobacter pylori-associated gastritis by aberrantly regulating NFIL3 via CagA activated ERK-SP1 pathway.